What Is Hollow Silica? Structure, Properties and Applications

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: Silica Supplier Middle East: Sourcing Options, Logistics and Key Markets
  • Keywords: sodium silicate
  • Published: 2026-11-20 06:58:54
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals

Toothpaste Grade Silica: Abrasive vs Thickening Silica, RDA Values and Specifications

Silica Oil Absorption: What It Means, Typical Values and How It Affects Formulations
One of the biggest challenges of tableting greatly potent APIs (antibiotics, hormones, cytostatic molecules) is to attain content uniformity [ 95, 96 ]. Since these molecules are used in small doses, it is demanding to attain a homogeneous powder mixture during mixing and to make sure this homogeneity until the end of tableting. Also, it is a hurdle to develop a reproducible method that ensures content uniformity for each production batch, since the specified dose must be made sure between batches, not just within one batch [ 95, 96 ]. A reliable alternative method is to use mesoporous silica as a carrier system rather than simple powder mixing, thus preventing the segregation and aggregation of the low-dose API during mixing and compression. In this case, the preloaded mesoporous carrier and the necessary excipients are mixed, and then the powder mixture can be compressed directly or after granulation. The drug loading can be controlled by the concentration of the drug solution used to fill the carrier systems, which affects the amount of the drug content in the concluding medicine [ 95, 96 ]. Based on this, nearly unlimitedly low doses can be formulated into tablets, even in a concentration of 0.01%, just by properly preparing the solution [ 96 ]. The technique is well-controllable and dependable, since each tablet has the same drug content and the desired content uniformity. Furthermore, the method can be used in both batch-based and continuous production [ 96 ]. This may be a promising finding because there is evidence that it is challenging to move from batch-based to continuous manufacturing while maintaining the desired drug content and content uniformity [ 94 ]. But it should be noted that in this study, no nanocarrier system was used [ 94 ], so utilizing MSN formulations could make an enormous improvement in developing continuous tablet manufacturing [ 96 ]. A study shown that MSN carriers can also be used in orodispersible films to enhance the dissolution of poorly water-soluble drugs [ 100 ]. Based on in vitro drug release studies, more than 90% of prednisolone was released within 2 min when the loaded MSN was incorporated into the formulation. This means a much faster, immediate release in comparison with formulations containing the free form of the drug. In addition, precise dosing can be accomplished utilizing nanocarriers for personalized medication; furthermore, enabling the production of low-dose preparations without content uniformity problems [ 100 ].
Silica as a Toothpaste Abrasive: How It Cleans and How RDA Is Controlled
95. Sun W.J., Aburub A., Sun C.C. A mesoporous silica based platform to enable tablet formulations of low dose drugs by direct compression. Int. J. Pharm. 2018;539:184-189. doi: 10.1016/j.ijpharm.2018.01.049. [ DOI ] [ PubMed ] [ Google Scholar ]
What Is Hydrated Silica? Uses in Toothpaste, Cosmetics and Food Explained
Silica for Electronic Encapsulation: Purity, CTE and Particle Size Requirements

What Is Low Alpha Silica? Why Alpha Emission Matters in Semiconductor Packaging

What is silica (SiO₂)?

600 mesh silica Mesoporous Silica Nanoparticles as Drug Delivery Systems

What is the difference between fumed silica and precipitated silica?

quartz powder for ceramics Tablets are the most used solid dosage form because of their numerous perks. They are characterized by excellent physical and chemical stability, high patient compliance, and productive economic production [ 92 ]. The incorporation of silica nanocarriers in tablet production presents a modern and innovative solution to diverse hurdles, boosting both the manufacturing process and therapeutic effectiveness. One of the considerable benefits of mesoporous silica carriers is their ability to stabilize the API in an amorphous state, which greatly improves its solubility [ 30, 39, 42, 43, 92 ]. This enhancement brings about a considerable increase in the dissolution rate of tablets, thereby improving bioavailability and resulting in more effective therapy [ 30, 39, 42, 92 ]. Furthermore, nanocarriers can effectively mask the bitter taste and unpleasant odor of the API, potentially further boosting patient compliance [ 42, 93 ]. Zhang et al. observed a considerable improvement in oral bioavailability with Telmisartan-loaded MSN carriers in vivo absorption studies conducted on dogs [ 24 ]. This MSN-containing tablet formulation was compared to commercially available tablets, with notable improvements attributed chiefly to the boosted permeability and solubility provided by the nanocarriers [ 24 ]. Moreover, the physical and chemical stability of the API may also improve, which is especially advantageous for sensitive molecules [ 39, 92 ].

What drives silica raw material prices?

electronic grade silica Even though MSNs can usually be recognized as secure products, their use during therapy may cause side impacts in the body [ 1, 2, 29 ]. Due to their small size and large surface area, they may tend to accumulate in the body, or certain organs (liver, spleen, kidney, lung) and may even be toxic in higher concentrations, which is a clear disadvantage [ 1, 4, 27 ]. The silanol groups (Si-OH) on their surface can interact with the phospholipid layer of the cell membrane, thereby causing cell lysis or, in extreme cases, hemolysis [ 4, 8 ]. In severe cases, the lack of hemocompatibility can also cause issues [ 2 ]. Overall, indications of cytotoxicity, haemotoxicity, and genotoxicity were also found [ 4, 8 ]. That is why the biocompatibility of all comparable preparations must be strictly controlled [ 2, 4, 27 ]. The physicochemical features (particle size, particle morphology, surface chemistry, pore structure, etc.) of nanocarriers also have a major impact on toxicity [ 2, 4, 8, 30 ]. Additionally, further attention must be paid to the biological influences of their decomposition products, because they may also cause unwanted side influences [ 1 ]. The breakdown of silica nanoparticles in the body can take up to a few days. The opening hydration is followed by hydrolysis, and, in the end, they are excreted in the urine in the form of silicic acid [ 1 ]. Nevertheless, the literature is contradictory in this regard [ 31 ]. Some experiments show no considerable cytotoxic effect [ 18, 31 ], while other experiments say otherwise [ 23, 32 ]. For example, an in vitro study was performed with multiple concentrations, surfaces, and particle sizes (60 nm, 100 nm, 300 nm) of MSNs, with an exposure time of 72 h [ 18 ]. This study shown no significant cytotoxic influence in any of the cell lines tested (human cervical (HeLA), epithelial lung (A549), and glioblastoma (U251)) [ 18 ]. Ismail et al. investigated the cytotoxic effect of silica nanoparticles in vivo in mouse models [ 33 ]. Amorphous silica nanoparticles were administered to the animals orally, at a dose of 150 mg/kg/day, for 3 months. Based on these mouse models, no toxic effects were detected under sub-chronic treatment of the nanoparticles [ 31 ]. In another study, particle size (15 nm, 60 nm, 200 nm) dependent impact was observed on cellular viability in all four cell lines tested (THP-1 derived macrophages, A549 epithelial cells, HaCaT keratinocytes, and NRK-52E kidney cells) [ 23 ]. Smaller particles caused notable toxicity on each cell line, after the exposure time of 24 h, in contrast to the larger particles, which demonstrated no cytotoxic impact [ 23 ]. A comparable outcome has been published to verify the toxic characteristic of mesoporous silica. In this in vitro study, the researchers investigated the effect of MSNs with an average size of 7 nm on cell viability at three different concentrations. After 72 h of exposure, only the highest concentration (62.5 µg/mL) caused a substantial decrease in cell viability of human lung fibroblast cells. This toxicity occurred in a time- and dose-dependent manner [ 32 ]. In an in vivo mouse model, MacCuaig et al. presented coating-dependent impacts after repeated intravenous administration of MSNs. Chitosan-coated MSNs induced minor organ changes and were the most biocompatible. Uncoated and especially PEG-coated MSNs (especially 2K PEG) moderately augmented pre-existing vascular or organ lesions, implying that PEGylation has the potential to augment chronic risks, while chitosan enables safer long-term use [ 34 ]. An in vitro study of Barguilla et al. exposed epithelial lung cells to bare, PEG-functionalized, or galacto-oligosaccharide-functionalized MSNs for eight weeks. There was no reported long-term DNA damage, but malignant-like alterations like anchorage-independent growth, boosted migration/invasion, and secretome-facilitated tumor promotion were triggered by PEG- and GAL-functionalized MSNs. Naked MSNs did not cause such alterations and were determined to be safer [ 35 ]. Coating, on the whole, exerts a significant impact on the safety of MSNs. Uncoated MSNs are relatively innocuous; the most biocompatible coatings were achieved with chitosan, but PEG and carbohydrate functionalization can be dangerous in the long run, from vascular toxicity in vivo to tumor-promoting activity in vitro [ 34, 35 ].

Cite this article: Silica Raw Materials News. "Silica COA: What a Certificate of Analysis Should Include and How to Verify It ." Published 2026-11-20 06:58:54. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.